Topical Dutasteride 0.025% 2ml once a week 7/18/2024
A user discusses using topical dutasteride 0.025% once a week for hair maintenance, alongside fortified minoxidil, RU58841, and Reviv Hair Serum. They seek feedback on the effectiveness of this regimen.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Fin/Min/Keto/Biotin - New Spray Topical
A user shared their hair loss treatment routine, which includes minoxidil, finasteride, ketoconazole, biotin, dutasteride, and RU58841. They recommend starting with topical sprays and mentioned using a new combo spray from Hims UK.
community Success without fin/dut??? Anyone? Please help :(
The conversation discusses alternatives to finasteride for hair loss, including topical treatments like minoxidil, RU58841, CB-03-01, and dutasteride. Users also mention other options like alfatradiol, topical caffeine, and mesotherapy, while expressing concerns about side effects and the effectiveness of these treatments.
community Dermatologist keeps stressing on diet and vitamins - are they that crucial?
The conversation is about a user experiencing increased hair loss after altering their treatment routine of oral dutasteride and topical minoxidil. The dermatologist emphasized the importance of diet and vitamins, but the user is skeptical given their healthy lifestyle.
community Why does this industry still revolve around 5-AR inhibitors?
Hair loss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.
community Taking Charge of Your Hair: The "Big 3 Stack" Explained for 2023
The "Big 3 Stack" for hair loss treatment, which includes Minoxidil for hair density improvement, Ketoconazole shampoo for enhancing hair volume and thickness, and Finasteride for blocking hair loss causing hormones. Microneedling can boost Minoxidil's effects.
Related Research
6 / 6 results
research Mechanistic synergy of hair growth promotion by the Avicennia marina extract and its active constituent (avicequinone C) in dermal papilla cells isolated from androgenic alopecia patients
In this study, researchers found that crude extracts from Avicennia marina and its component avicequinone C inhibit mechanisms contributing to androgenic alopecia in vitro, including 5α-reductase activity and DHT-AR interactions, potentially promoting hair growth and delaying the catagen phase in human dermal papilla cells.
research Encapsulación en ciclodextrinas de compuestos con actividad frente a la alopecia androgénica masculina.
This research focused on formulating finasteride, dutasteride, and minoxidil with cyclodextrins to enhance their solubility and skin penetration for topical use, potentially reducing scalp irritation from current alcohol-based preparations.
research Cosmetic Approach for Men
This chapter reviews differences in dermatological treatments and conditions between male and female patients, particularly noting the impacts of sex steroids on various skin processes, but presents no new clinical findings.
research Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review
This review discusses the potential of using SULT1A1 expression in the scalp as a biomarker to predict response to minoxidil treatment for androgenetic alopecia, but reports no new clinical results.
research Pharmacotherapy of androgenetic alopecia – a literature review
This review discusses various pharmacotherapies for androgenetic alopecia, concluding that combination therapies may offer more effective treatment, though more research on alternative preparations is needed.
research Manage androgenetic alopecia in men with established options but emerging therapies show promise
This study discusses treatment options for androgenetic alopecia, highlighting that while available therapies include approved and off-label pharmacological agents and non-pharmacological treatments, there is still limited evidence-based guidance on managing this common hair loss disorder.